Allogene Therapeutics (ALLO)

• Market cap: $780M
• 1 day: 0.44%
• 5 days: 20.21%
• 1 month: 3.2%
• 3 months: -14.72%
• 6 months: 54.79%
• Year to date: 67.41%
• 1 year: 98.25%
• 5 years: -91.21%
• 10 years: -90.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Employees: 152